This is a working overview of Tetrapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-18 and is reviewed periodically as new material appears.
Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.
Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Ala-Glu-Asp-Gly | Often abbreviated AEDG in research literature |
| Common synonyms | Epithalon, epitalon, AEDG | Spelling variants refer to the same tetrapeptide |
| Molecular formula | C14H22N4O9 | Theoretical monoisotopic mass near 390.35 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility class | Freely soluble in water | Hydrophilic peptide; dissolves in aqueous buffer |
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
Discussions in the literature often conflate three distinct entities: the pineal extract epithalamin, the isolated tetrapeptide AEDG, and commercial preparations sold under similar names. Reviews citing older Russian-language studies sometimes omit detail on purity, route of administration and control groups, which makes cross-study comparison difficult. Researchers working with the compound generally note the need for independent replication, standardized enzyme assays, and clearer reporting of peptide identity. These caveats are relevant when weighing claims that appear in secondary sources rather than in primary reports.
（TG:@pojiaai）Epitalon is a synthetic linear tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. It emerged from work on epithalamin, a peptide fraction prepared from bovine pineal tissue, and was designed as a short, chemically defined analogue of that extract. Early publications came mainly from Russian laboratories studying pineal peptides and aging-related endpoints. The compound appears in the literature under several spellings, including epithalon and epithalone, which complicates systematic searching. Its small size makes solid-phase assembly and routine analytical characterization straightforward.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
Epitalon is the common name for a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, usually abbreviated AEDG. All four residues are proteinogenic amino acids, and the free peptide has a calculated mass near 390 grams per mole. Because the chain is short and carries no modifications, it is assembled readily by solid-phase synthesis and is distributed mainly as a freeze-dried solid for laboratory work. Catalogue listings use the spellings epitalon, epithalone, and simply AEDG, and the three refer to the same sequence.
The idea of a guerrilla organization was conceived as early as October 1941, months before the Philippines' entry to World War II. As early as 1941, Juan Feleo, a well-known peasant leader and member of the Partido Komunista ng Pilipinas (PKP), had begun to mobilize peasants in his home province of Nueva Ecija for the conflict. Pedro Abad Santos, The founding member of the Socialist Party of the Philippines, had also ordered Luis Taruc to mobilize forces in Pampanga. At the outbreak of World War II in the Philippines and the capture of Manila, top-ranking leaders of the PKP were captured by the Japanese military. Crisanto Evangelista, its founder, was among those who were captured and executed in 1942. Abad Santos was similarly captured but was released in 1943. Dr. Vicente Lava took the reins of the PKP and tried to re-organize the party. In February 1942, a "struggle conference" was held in Cabiao, Nueva Ecija to discuss organization, strategy, and tactics. Members of the PKP, the Popular Front Party, the League for the Defense of Democracy, KPMP, AMT, and KAP convened to create a structure for unified resistance against the Japanese. A united front tactic was agreed upon as a means of attracting the broadest sections of population, not necessarily communists. A three-front resistance was agreed upon: military, political, and economic. The military aim was to harass the Japanese continuously and keep it off-balance so as to prevent it from focusing on activities aimed at winning the goodwill of the people.
=== Diapause === C. brunneus overwinter via obligate egg diapause. Research suggests that diapause can be broken regardless of the stage of development. Eggs can be kept for up to a year at 5 °C and still hatch. In the lab, diapause can be broken by keeping the eggs at 25 °C for two weeks before lowering the temperature to approximately 4 °C for several weeks.
== Experimental evidence == When Pauling and Corey first proposed the alpha sheet, they suggested that it agreed well with fiber diffraction results from beta-keratin fibers. However, since the alpha sheet did not appear to be energetically favorable, they argued that beta sheets would occur more commonly among normal proteins, and subsequent demonstration that beta-keratin is made of beta sheets consigned the alpha sheet proposal to obscurity. However the alpha strand conformation is observed in isolated instances in native state proteins as solved by X-ray crystallography or protein NMR, although an extended alpha sheet is not identified in any known natural protein. Native proteins containing alpha-strand regions or alpha-sheet-patterned hydrogen bonding include synaptotagmin, lysozyme, and potassium channels, where the alpha-strands line the ion-conducting pore. Evidence for the existence of alpha-sheet in a mutant form of transthyretin has been presented. Alpha-sheet conformations have been observed in crystal structures of short non-natural peptides, especially those containing a mixture of L and D amino acids. The first crystal structure containing an alpha sheet was observed in the capped tripeptide Boc–AlaL–a-IleD–IleL–OMe. Other peptides that assume alpha-sheet structures include capped diphenyl-glycine-based dipeptides and tripeptides.
In this manner, some became tied to the very parcel of land into which they had been born a slave having little freedom or economic opportunity because of Jim Crow laws which perpetuated discrimination, limited education, promoted persecution without due process and resulted in continued poverty. Fear of reprisals such as unjust incarcerations and lynchings deterred upward mobility further.
== The route == Though the route changes to accommodate various ports of call, the race typically departs Europe in October, and in recent editions has had either 9 or 10 legs, with in-port races at many of the stopover cities. The 2008–09 race started in Alicante, Spain, on October 11, 2008. The route for the 2008–2009 race was altered from previous years to include stopovers in India and Asia for the first time. The 2008–09 route covered nearly 39,000 nmi (72,000 km), took over nine months to complete, and reached a cumulative TV audience of 2 billion people worldwide. During the nine months of the 2011–12 Volvo Ocean Race, which started in Alicante, Spain, in October 2011 and concluded in Galway, Ireland, in July 2012, the teams were scheduled to sail over 39,000 nmi (72,000 km) of the world's most treacherous seas via Cape Town, Abu Dhabi, Sanya, Auckland, around Cape Horn to Itajaí, Miami, Lisbon, and Lorient. As in the previous editions, the 2014–15 Volvo Ocean Race started in Alicante, Spain, on October 11. Destination was Gothenburg, Sweden, scheduled for June 2015, with stopovers in the ports of Cape Town, Abu Dhabi, Sanya, Auckland, Itajaí, Newport, Lisbon, Lorient, and with a Pitstop at The Hague through the last leg.
Sources: en.wikipedia.org
== Initial investigations == Concerns about an increase in infant collapses and deaths in the neonatal unit at the Countess of Chester Hospital first arose in June 2015, when four collapses occurred, three of them fatal. The unit normally recorded two or three deaths a year. The unit manager, Eirian Powell, and unit lead clinician Brearey carried out an informal review and reported the incidents to the trust's serious‑incident committee, which classified the deaths as medication errors. Brearey noted that Letby had been on duty for each incident but regarded this as an unsurprising coincidence, given staffing levels. He later told the statutory inquiry that no concerns had been raised about her practice at the time. Subsequent reporting in 2023 indicated that he had developed suspicions earlier and believed the trust failed to act on them. A Care Quality Commission inspection in February 2016 heard concerns about difficulties raising issues with managers but was not informed of an elevated mortality rate. Its report highlighted staffing and skill‑mix problems but described a generally positive organisational culture. In May 2016, the trust's executive team concluded that the rise in deaths was coincidental. National MBRRACE‑UK data later showed that the unit's neonatal death rate between June 2015 and June 2016 was at least 10 per cent higher than expected, with deaths in 2015 double those of the previous year. On 24 June 2016, following two further deaths, Brearey asked the duty executive to remove Letby from clinical duties, but was told she was safe to work.
=== Contestants === 1st - Blayre Wright, Bakery Owner from Lancaster, Pennsylavania 2/3/4th - Zac Mercer, Bakery Owner from Denver, Colorado 2/3/4th - Lauren Rodgers, Bakery Owner from Olympia, Washington 2/3/4th - Jill Davis, Bakery Owner from Owosso, Michigan 5th - Kristi Descher, Pastry Chef from Valencia, California 6th - Alexey Ivanov, Home Baker from Brooklyn, New York 7th - Lola Forbes, Bakery Co-Owner from Mesa, Arizona 8th - Maricsa Trejo, Bakery Owner from Richardson, Texas 9th - Justin Dominguez, Bakery Owner and Cake Artist from San Antonio, Texas 9th - Margarita Garcia, Pastry Chef from Miami, Florida 11th - Marcus Brackett, Self-Taught Baker from Rockville, Maryland 12th - AJ DeDiego, Home Baker from Atlanta, Georgia
=== Cage-free eggs === In 2022, Outback Steakhouse's parent company, Bloomin' Brands, announced their commitment to source 100% cage-free eggs across all of their locations by 2030. In 2024, they reported that they had reached this goal in their United States locations.
=== Defense against infections === PGLYRP2 plays a limited role in host defense against infections. PGLYRP2-deficient mice are more sensitive to Pseudomonas aeruginosa-induced keratitis and Streptococcus pneumoniae-induced pneumonia and sepsis. However, PGLYRP2-deficient mice did not show a changed susceptibility to systemic Escherichia coli, Staphylococcus aureus, and Candida albicans infections or intestinal Salmonella enterica infection, although the latter was accompanied by increased inflammation in the cecum. Although PGLYRP2 is not directly bacteriolytic, it has antibacterial activity against both Gram-positive and Gram-negative bacteria and Chlamydia trachomatis. Human and mouse PGLYRP2 promote hepatitis B virus (HBV) clearance in vitro in hepatocytes and in HBV-infected mice. PGLYRP2 through its HBV DNA-binding domain recognizes covalently closed circular DNA (cccDNA) of HBV sequestering it in the nucleus and separating it from the cellular viral replication machinery. Additionally, PGLYRP2 suppresses HBV capsid assembly by directly interacting through its PGRP domain with the viral capsid and promoting secretion of the PGLYRP2-HBV capsid complexes.
Sources: en.wikipedia.org
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine–glutamate–aspartate–glycine, also written AEDG. It was developed in Russian gerontology research and is studied for proposed effects on telomerase, melatonin regulation, and neuroendocrine function. It is not an approved pharmaceutical in the United States or the European Union.
No. Epithalamin is a peptide-rich extract prepared from bovine pineal glands, while epitalon is a short synthetic peptide designed as a defined analogue of it. The synthetic version was intended to provide a reproducible molecule with some of the same proposed biological activity.
Telomere elongation and telomerase activation have been reported in cultured human somatic cells, but evidence from living human subjects is limited and has not been independently confirmed at scale. Reported findings come largely from small studies with differing designs, so the question remains open rather than settled.
No. Epithalamin is a heterogeneous peptide fraction obtained from pineal gland extract and contains many components. Epitalon is a single synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. Researchers synthesised the shorter peptide while attempting to identify active sequences within the extract.